鼠李糖乳杆菌对炎症性肠病的影响机制研究进展

doi:10.12114/j.issn.1007-9572.2022.0330

中国全科医学 ›› 2022, Vol. 25 ›› Issue (36): 4595-4600.DOI: 10.12114/j.issn.1007-9572.2022.0330

鼠李糖乳杆菌对炎症性肠病的影响机制研究进展

岑秋宇¹, 庞日朝², 崔艳如¹, 魏娟芳¹, 张安仁³^,^*()

1.610075　四川省成都市，成都中医药大学养生康复学院
2.610083　四川省成都市，中国人民解放军西部战区总医院康复医学科
3.200434　上海市，同济大学附属上海市第四人民医院康复医学科

收稿日期:2022-05-22 修回日期:2022-06-25 出版日期:2022-12-20 发布日期:2022-09-22
通讯作者: 张安仁
岑秋宇，庞日朝，崔艳如，等.鼠李糖乳杆菌对炎症性肠病的影响机制研究进展[J].中国全科医学，2022，25（36）：4595-4600. [www.chinagp.net]
作者贡献：岑秋宇进行文章的构思与设计；崔艳如进行文献/资料收集；岑秋宇进行文献/资料整理；岑秋宇撰写论文；魏娟芳进行论文的修订；张安仁、庞日朝负责文章的质量控制及审校；张安仁、庞日朝文章整体负责，监督管理。
基金资助:
国家自然科学基金面上项目(81973927)

Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease

CEN Qiuyu¹, PANG Rizhao², CUI Yanru¹, WEI Juanfang¹, ZHANG Anren³^,^*()

1.School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
2.Department of Rehabilitation Medicine, General Hospital of the Western Theater of the Chinese People's Liberation Army, Chengdu 610083, China
3.Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

Received:2022-05-22 Revised:2022-06-25 Published:2022-12-20 Online:2022-09-22
Contact: ZHANG Anren
About author:
CEN Q Y, PANG R Z, CUI Y R, et al. Advances in the mechanism of Lactobacillus rhamnosus GG improving inflammatory bowel disease [J] . Chinese General Practice, 2022, 25 (36) : 4595-4600.

分享到

摘要/Abstract

摘要： 炎症性肠病（IBD）在我国的发病率逐年上升。随着微生物-宿主相互作用的发现，人们意识到肠道微生物群对IBD的发生、发展至关重要。由此提示，从调节肠道微生物角度出发，可能是治疗IBD的新策略。鼠李糖乳杆菌（LGG）是目前应用广泛的益生菌菌株之一，其可通过调节肠道微生物组成、维持肠上皮屏障完整性、调节肠道免疫反应、抑制氧化应激、改善焦虑抑郁状态等途径达到缓解IBD的目的。因此，本文就LGG对IBD的作用机制做一综述，以期为其临床应用提供理论支持。

关键词: 肠疾病, 炎症性肠病, 鼠李糖乳杆菌, 胃肠道微生物组, 肠-脑轴

Abstract:

China is seeing an increasing prevalence of inflammatory bowel disease (IBD) . During the process of exploring treatments for IBD, gut microbiota has been found to be crucial to the development of IBD along with the discovery of microbial-host interactions, suggesting that modulating gut microbiota may be a new strategy for the treatment of IBD. Recent studies have shown that Lactobacillus rhamnosus GG (LGG) , one most widely used probiotic strain, can achieve IBD alleviation by regulating intestinal microbial composition, maintaining intestinal epithelial barrier integrity, modulating intestinal immune response, inhibiting oxidative stress, and improving anxiety-depression status. Therefore, this paper presents a review of the mechanism of action of LGG in improving IBD, providing theoretical support for its clinical application.

Key words: Intestinal diseases, Inflammatory bowel disease, Lactobacillus rhamnosus, Gastrointestinal microbiome, Gut-brain axis

岑秋宇,庞日朝,崔艳如,等. 鼠李糖乳杆菌对炎症性肠病的影响机制研究进展[J]. 中国全科医学, 2022, 25(36): 4595-4600. DOI: 10.12114/j.issn.1007-9572.2022.0330.
CEN Qiuyu,PANG Rizhao,CUI Yanru, et al. Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease[J]. Chinese General Practice, 2022, 25(36): 4595-4600. DOI: 10.12114/j.issn.1007-9572.2022.0330.

图/表 2

参考文献 49

[1]	ORDÁS I, ECKMANN L, TALAMINI M, et al. Ulcerative colitis[J]. Lancet，2012，380(9853):1606-1619. DOI：10.1016/S0140-6736(12)60150-0.
[2]	HODSON R. Inflammatory bowel disease[J]. Nature，2016，540(7634):S97. DOI：10.1038/540S97a.
[3]	ZHANG Y Z, LI Y Y. Inflammatory bowel disease：pathogenesis[J]. World J Gastroenterol，2014，20(1):91-99. DOI：10.3748/wjg.v20.i1.91.
[4]	TORRES J, MEHANDRU S, COLOMBEL J F, et al. Crohn's disease[J]. Lancet，2017，389(10080):1741-1755. DOI：10.1016/S0140-6736(16)31711-1.
[5]	ROUND J L, MAZMANIAN S K. The gut microbiota shapes intestinal immune responses during health and disease[J]. Nat Rev Immunol，2009，9(5):313-323. DOI：10.1038/nri2515.
[6]	KIM D, JUNG J Y, OH H S, et al. Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis[J]. BMC Gastroenterol，2021，21(1):396. DOI：10.1186/s12876-021-01975-3.
[7]	LEHMANN T, SCHALLERT K, VILCHEZ-VARGAS R, et al. Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis[J]. J Proteomics，2019，201:93-103. DOI：10.1016/j.jprot.2019.04.009.
[8]	FACCHIN S, VITULO N, CALGARO M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease[J]. Neurogastroenterol Motil，2020，32(10):e13914. DOI：10.1111/nmo.13914.
[9]	IMAI T, INOUE R, KAWADA Y, et al. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease[J]. J Gastroenterol，2019，54(2):149-159. DOI：10.1007/s00535-018-1530-7.
[10]	WEINGARDEN A R, VAUGHN B P. Intestinal microbiota，fecal microbiota transplantation，and inflammatory bowel disease[J]. Gut Microbes，2017，8(3):238-252. DOI：10.1080/19490976.2017.1290757.
[11]	DORON S, SNYDMAN D R, GORBACH S L. Lactobacillus GG：bacteriology and clinical applications[J]. Gastroenterol Clin North Am，2005，34(3):483-498,ix. DOI：10.1016/j.gtc.2005.05.011.
[12]	唐昱婷，汤加勇，赵华. 鼠李糖乳杆菌对肠道屏障功能的影响机制研究进展[J]. 四川农业大学学报，2021，39(4):427-432. DOI：10.16036/j.issn.1000-2650.2021.04.002.
[13]	SEGERS M E, LEBEER S. Towards a better understanding of Lactobacillus rhamnosus GG—host interactions[J]. Microb Cell Fact，2014，13(Suppl 1):S7. DOI：10.1186/1475-2859-13-S1-S7.
[14]	MENTELLA M C, SCALDAFERRI F, PIZZOFERRATO M, et al. Nutrition，IBD and gut microbiota：a review[J]. Nutrients，2020，12(4):E944. DOI：10.3390/nu12040944.
[15]	LANE E R, ZISMAN T L, SUSKIND D L. The microbiota in inflammatory bowel disease：current and therapeutic insights[J]. J Inflamm Res，2017，10:63-73. DOI：10.2147/JIR.S116088.
[16]	NI J, WU G D, ALBENBERG L, et al. Gut microbiota and IBD：causation or correlation? [J]. Nat Rev Gastroenterol Hepatol，2017，14(10):573-584. DOI：10.1038/nrgastro.2017.88.
[17]	TAKAHASHI K, NISHIDA A, FUJIMOTO T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease[J]. Digestion，2016，93(1):59-65. DOI：10.1159/000441768.
[18]	MIRSEPASI-LAURIDSEN H C, VALLANCE B A, KROGFELT K A, et al. Escherichia coli pathobionts associated with inflammatory bowel disease[J]. Clin Microbiol Rev，2019，32(2):e00060-e00018. DOI：10.1128/CMR.00060-18.
[19]	YEO S, PARK H, SEO E, et al. Anti-inflammatory and gut microbiota modulatory effect of Lactobacillus rhamnosus strain LDTM 7511 in a dextran sulfate sodium-induced colitis murine model[J]. Microorganisms，2020，8(6):E845. DOI：10.3390/microorganisms8060845.
[20]	TONG L J, ZHANG X Y, HAO H N, et al. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice[J]. Nutrients，2021，13(10):3319. DOI：10.3390/nu13103319.
[21]	RALLABANDI H R, YANG H, OH K B, et al. Evaluation of intestinal epithelial barrier function in inflammatory bowel diseases using murine intestinal organoids[J]. Tissue Eng Regen Med，2020，17(5):641-650. DOI：10.1007/s13770-020-00278-0.
[22]	ODENWALD M A, TURNER J R. The intestinal epithelial barrier：a therapeutic target? [J]. Nat Rev Gastroenterol Hepatol，2017，14(1):9-21. DOI：10.1038/nrgastro.2016.169.
[23]	YOO J H, DONOWITZ M. Intestinal enteroids/organoids：a novel platform for drug discovery in inflammatory bowel diseases[J]. World J Gastroenterol，2019，25(30):4125-4147. DOI：10.3748/wjg.v25.i30.4125.
[24]	LEBEER S, CLAES I, TYTGAT H L, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells[J]. Appl Environ Microbiol，2012，78(1):185-193. DOI：10.1128/AEM.06192-11.
[25]	FATMAWATI N N D, GOTOH K, MAYURA I P B, et al. Enhancement of intestinal epithelial barrier function by Weissella confusa F213 and Lactobacillus rhamnosus FBB81 probiotic candidates in an in vitro model of hydrogen peroxide-induced inflammatory bowel disease[J]. BMC Res Notes，2020，13(1):489. DOI：10.1186/s13104-020-05338-1.
[26]	ORLANDO A, LINSALATA M, BIANCO G, et al. Lactobacillus rhamnosus GG protects the epithelial barrier of wistar rats from the pepsin-trypsin-digested gliadin（PTG）-induced enteropathy[J]. Nutrients，2018，10(11):E1698. DOI：10.3390/nu10111698.
[27]	HAN X, LEE A, HUANG S, et al. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids[J]. Gut Microbes，2019，10(1):59-76. DOI：10.1080/19490976.2018.1479625.
[28]	FIECHTER R H, DE JONG H M, VAN MENS L J J, et al. IL-12p40/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and wnt[J]. Front Immunol，2021，12:611656. DOI：10.3389/fimmu.2021.611656.
[29]	YAN F, CAO H W, COVER T L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism[J]. J Clin Invest，2011，121(6):2242-2253. DOI：10.1172/JCI44031.
[30]	GUAN Q D. A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J]. J Immunol Res，2019，2019:7247238. DOI：10.1155/2019/7247238.
[31]	GEREMIA A, BIANCHERI P, ALLAN P, et al. Innate and adaptive immunity in inflammatory bowel disease[J]. Autoimmun Rev，2014，13(1):3-10. DOI：10.1016/j.autrev.2013.06.004.
[32]	JIN Y B, CAO X, SHI C W, et al. Lactobacillus rhamnosus GG promotes early B lineage development and IgA production in the Lamina propria in piglets[J]. J Immunol，2021，207(8):2179-2191. DOI：10.4049/jimmunol.2100102.
[33]	YANG L Y, HIGGINBOTHAM J N, LIU L P, et al. Production of a functional factor，p40，by Lactobacillus rhamnosus GG is promoted by intestinal epithelial cell-secreted extracellular vesicles[J]. Infect Immun，2019，87(7):e113-119. DOI：10.1128/IAI.00113-19.
[34]	SHEN X, LIU L P, PEEK R M, et al. Supplementation of p40，a Lactobacillus rhamnosus GG-derived protein，in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes[J]. Mucosal Immunol，2018，11(5):1316-1328. DOI：10.1038/s41385-018-0034-3.
[35]	WANG Y, GONG L, WU Y P, et al. Oral administration of Lactobacillus rhamnosus GG to newborn piglets augments gut barrier function in pre-weaning piglets[J]. J Zhejiang Univ Sci B，2019，20(2):180-192. DOI：10.1631/jzus.B1800022.
[36]	JIA L, WU R Q, HAN N N, et al. Porphyromonas gingivalis and Lactobacillus rhamnosus GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2[J]. Clin Transl Immunology，2020，9(11):e1213. DOI：10.1002/cti2.1213.
[37]	LI Y B, YANG S J, LUN J X, et al. Inhibitory effects of the Lactobacillus rhamnosus GG effector protein HM0539 on inflammatory response through the TLR4/MyD88/NF-кB axis[J]. Front Immunol，2020，11:551449. DOI：10.3389/fimmu.2020.551449.
[38]	LIU T Y, SONG X L, AN Y P, et al. Lactobacillus rhamnosus GG colonization in early life ameliorates inflammaging of offspring by activating SIRT1/AMPK/PGC-1 α pathway[J]. Oxid Med Cell Longev，2021，2021:3328505. DOI：10.1155/2021/3328505.
[39]	LIU P, LI Y X, WANG R, et al. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease[J]. Biomedicines，2021，10(1):85. DOI：10.3390/biomedicines10010085.
[40]	BHATTACHARYYA A, CHATTOPADHYAY R, MITRA S, et al. Oxidative stress：an essential factor in the pathogenesis of gastrointestinal mucosal diseases[J]. Physiol Rev，2014，94(2):329-354. DOI：10.1152/physrev.00040.2012.
[41]	GOYAL N, RISHI P, SHUKLA G. Lactobacillus rhamnosus GG antagonizes Giardia intestinalis induced oxidative stress and intestinal disaccharidases：an experimental study[J]. World J Microbiol Biotechnol，2013，29(6):1049-1057. DOI：10.1007/s11274-013-1268-6.
[42]	CHIVERO E T, SIL S, SINGH S, et al. Protective role of Lactobacillus rhamnosus probiotic in reversing cocaine-induced oxidative stress，glial activation and locomotion in mice[J]. J Neuroimmune Pharmacol，2021. DOI：10.1007/s11481-021-10020-9.
[43]	LI J Z, LI Q K, GAO N, et al. Exopolysaccharides produced by Lactobacillus rhamnosus GG alleviate hydrogen peroxide-induced intestinal oxidative damage and apoptosis through the Keap1/Nrf2 and Bax/Bcl-2 pathways in vitro[J]. Food Funct，2021，12(20):9632-9641. DOI：10.1039/d1fo00277e.
[44]	EUGENICOS M P, FERREIRA N B. Psychological factors associated with inflammatory bowel disease[J]. Br Med Bull，2021，138(1):16-28. DOI：10.1093/bmb/ldab010.
[45]	BARBERIO B, ZAMANI M, BLACK C J, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease：a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol，2021，6(5):359-370. DOI：10.1016/S2468-1253(21)00014-5.
[46]	SWEENEY P, O'HARA K, XU Z, et al. HFD-induced energy states-dependent bidirectional control of anxiety levels in mice[J]. Int J Obes（Lond），2017，41(8):1237-1245. DOI：10.1038/ijo.2017.112.
[47]	FOROOZAN P, KOUSHKIE JAHROMI M, NEMATI J, et al. Probiotic supplementation and high-intensity interval training modify anxiety-like behaviors and corticosterone in high-fat diet-induced obesity mice[J]. Nutrients，2021，13(6):1762. DOI：10.3390/nu13061762.
[48]	ZHOU B Q, JIN G, PANG X Q, et al. Lactobacillus rhamnosus GG colonization in early life regulates gut-brain axis and relieves anxiety-like behavior in adulthood[J]. Pharmacol Res，2022，177:106090. DOI：10.1016/j.phrs.2022.106090.
[49]	MEINI S, LAUREANO R, FANI L, et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis：case report and review of the literature[J]. Infection，2015，43(6):777-781. DOI：10.1007/s15010-015-0798-2.

研究者	受试样本	丰度降低的肠道菌群	丰度增加的肠道菌群
KIM等^[6]	16例UC患者和15例健康者	Bacteroidetes	Fusobacteria、Proteobacteria
LEHMANN等^[7]	14例UC患者和17例健康者	Phyla Bacteroidetes、Spirochaetes、Tenericutes	—
FACCHIN等^[8]	30例UC患者和18例健康者	Lachnospiraceae、Ruminoclostridium	Clostridium
IMAI等^[9]	20例CD患者和20例健康者	phyla Firmicutes、Bacteroidetes、Faecalibacterium	Enterococcus
LEHMANN等^[7]	11例CD患者和17例健康者	Acidobacteria	—
FACCHIN等^[8]	19例CD患者和18例健康者	Feacalibacterium、Akkermansia、Lachnospiraceae	Anaerotruncus、Oscillospira

研究者	受试样本	丰度降低的肠道菌群	丰度增加的肠道菌群
KIM等^[6]	16例UC患者和15例健康者	Bacteroidetes	Fusobacteria、Proteobacteria
LEHMANN等^[7]	14例UC患者和17例健康者	Phyla Bacteroidetes、Spirochaetes、Tenericutes	—
FACCHIN等^[8]	30例UC患者和18例健康者	Lachnospiraceae、Ruminoclostridium	Clostridium
IMAI等^[9]	20例CD患者和20例健康者	phyla Firmicutes、Bacteroidetes、Faecalibacterium	Enterococcus
LEHMANN等^[7]	11例CD患者和17例健康者	Acidobacteria	—
FACCHIN等^[8]	19例CD患者和18例健康者	Feacalibacterium、Akkermansia、Lachnospiraceae	Anaerotruncus、Oscillospira

鼠李糖乳杆菌对炎症性肠病的影响机制研究进展

Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease

RichHTML

PDF

PDF (英文版)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 49

相关文章 15

编辑推荐

Metrics

留言

[1]	肖礼其, 杨莉, 崔赛仙, 张娅袁, 王玉路, 何燕. 高盐诱导肠道菌群紊乱调节盐敏感性血压的机制研究[J]. 中国全科医学, 2023, 26(29): 3704-3709.
[2]	蒲瑜, 张吉翔, 董卫国. 铁死亡与炎症性肠病的研究进展[J]. 中国全科医学, 2023, 26(29): 3698-3703.
[3]	张振东, 蔡斌, 王宏伟, 乔增勇. 肠道菌群及其代谢产物苯乙酰谷氨酰胺在慢性心力衰竭患者中的变化研究[J]. 中国全科医学, 2023, 26(29): 3665-3673.
[4]	陈晓芬, 陈钰涵, 马娟. 炎症性肠病新型治疗方法的研究进展[J]. 中国全科医学, 2023, 26(27): 3349-3354.
[5]	段玉霞, 李珍, 张斯齐, 房志学, 秦月兰. 结直肠癌诊疗中患者决策辅助工具应用效果的系统评价[J]. 中国全科医学, 2023, 26(25): 3194-3201.
[6]	秦宇宁, 赵天易, 刘凤斌, 王鑫, 曹雪, 孙铭璘, 赖科云, 邸露瑶, 葛志闪, 刘松, 邢颖, 杨蕾, 岳俐宏, 邹梅梅, 何丽云, 李洪皎. 中文版胃肠道症状评定量表对胃肠道疾病患者测量学特性研究[J]. 中国全科医学, 2023, 26(18): 2277-2285.
[7]	傅伟强, 周剑波, 吴雄健, 黄才斌. 肠道菌群视角下非酒精性脂肪性肝病的治疗策略[J]. 中国全科医学, 2023, 26(06): 742-748.
[8]	邵薇, 黄蒙蒙, 贺丹丹, 黄福鑫, 牛红月. 缺血性卒中后功能性消化不良严重程度的影响因素研究[J]. 中国全科医学, 2022, 25(36): 4509-4514.
[9]	罗建峰, 侯江涛, 侯政昆, 彭彬, 李辉标, 刘诗颖, 何镇帆, 钟嘉敏, 张诗静, 刘凤斌, 陈新林. 基于中医理论构建炎症性肠病患者报告结局量表及条目筛选研究[J]. 中国全科医学, 2022, 25(29): 3672-3677.
[10]	莫蕾, 钟萍. 孕早中期孕妇肠道菌群差异与子痫前期发病关系的研究[J]. 中国全科医学, 2022, 25(20): 2489-2492.
[11]	肖雪, 王宇琦, 赖晓岚, 钟绍涛, 赵翠柳, 刘丹, 李琳, 谭荣韶, 杨红玲. 孕妇肠道菌群对新生儿出生体质量的影响研究[J]. 中国全科医学, 2022, 25(19): 2363-2370.
[12]	黄筱钧, 杨锦, 雷亚琪美, 曾志杰, 金朝晖. 以肠道菌群为靶点的新型辅助降压模式研究进展[J]. 中国全科医学, 2022, 25(18): 2297-2302.
[13]	岑秋宇, 庞日朝, 胡晓敏, 崔艳如, 张安仁. 罗伊乳杆菌对肠屏障功能调节作用的研究进展[J]. 中国全科医学, 2022, 25(15): 1918-1922.
[14]	黄虹玉, 雷甜甜, 马洪升, 胡仁伟, 杨锦林. 以巨大足部溃疡为表现的坏疽性脓皮病伴克罗恩病一例报道并文献复习[J]. 中国全科医学, 2022, 25(15): 1906-1909.
[15]	刘展鹏, 杨晓钟, 陈梦雪, 张梦辉, 王宏刚. 炎症性肠病症状量表评估炎症性肠病疾病活动度的临床价值研究[J]. 中国全科医学, 2022, 25(14): 1713-1718.